Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative enfortumab vedotin plus pembrolizumab versus neoadjuvant gemcitabine plus cisplatin in cisplatin-eligible muscle-invasive bladder cancer
2023-505615-21-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma (TCC) comparing Perioperative enfortumab vedotin plus pembrolizumab with Neoadjuvant gemcitabine plus cisplatin (2 arms). Primary endpoint: Event-Free Survival. Planned start Apr 2021; status: authorised.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-505615-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505615-21-00.